Clinical Trials Logo

Cerebral Aspergillosis clinical trials

View clinical trials related to Cerebral Aspergillosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04486885 Recruiting - Clinical trials for Invasive Aspergillosis

European Study of Cerebral Aspergillosis Treated With Isavuconazole

ESCAI
Start date: August 1, 2021
Phase:
Study type: Observational

Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile. The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.